Published in Proc Natl Acad Sci U S A on July 26, 2004
Molecular dynamics: survey of methods for simulating the activity of proteins. Chem Rev (2006) 3.18
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". Structure (2009) 2.83
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 2.61
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem (2008) 2.14
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Molecular dynamics simulations and drug discovery. BMC Biol (2011) 1.91
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 1.83
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology (2008) 1.79
Resistance to integrase inhibitors. Viruses (2010) 1.75
Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc Natl Acad Sci U S A (2008) 1.73
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology (2007) 1.55
HIV-1 IN inhibitors: 2010 update and perspectives. Curr Top Med Chem (2009) 1.53
Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology (2008) 1.48
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol (2010) 1.32
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol (2007) 1.31
Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J Virol (2007) 1.30
Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol (2009) 1.30
Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology (2009) 1.29
Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol (2012) 1.28
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol (2008) 1.27
Subunit-specific protein footprinting reveals significant structural rearrangements and a role for N-terminal Lys-14 of HIV-1 Integrase during viral DNA binding. J Biol Chem (2007) 1.26
Molecular Interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration. J Mol Biol (2009) 1.19
Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother (2013) 1.18
Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrob Agents Chemother (2005) 1.16
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology (2010) 1.13
Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends. J Biol Chem (2005) 1.13
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother (2008) 1.10
Emerging methods for ensemble-based virtual screening. Curr Top Med Chem (2010) 1.08
Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA. J Mol Biol (2006) 1.07
Biomolecularmodeling and simulation: a field coming of age. Q Rev Biophys (2011) 1.06
Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother (2008) 1.05
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother (2010) 1.04
Authentic HIV-1 integrase inhibitors. Future Med Chem (2010) 1.04
Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity. Biology (Basel) (2012) 1.03
Defining the DNA substrate binding sites on HIV-1 integrase. J Mol Biol (2008) 1.01
A dynamic model of HIV integrase inhibition and drug resistance. J Mol Biol (2010) 0.99
Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem (2008) 0.98
Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother (2005) 0.97
Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors. Biochemistry (2010) 0.96
Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology (2007) 0.95
Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother (2008) 0.94
Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93
Recent progress in antiretrovirals--lessons from resistance. Drug Discov Today (2008) 0.92
siRNA screening of a targeted library of DNA repair factors in HIV infection reveals a role for base excision repair in HIV integration. PLoS One (2011) 0.90
HIV resistance to raltegravir. Eur J Med Res (2009) 0.89
Discovery of Staphylococcus aureus sortase A inhibitors using virtual screening and the relaxed complex scheme. Chem Biol Drug Des (2013) 0.89
Symmetrical recognition of cellular DNA target sequences during retroviral integration. Proc Natl Acad Sci U S A (2005) 0.88
Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag (2008) 0.87
Current and emerging opportunities for molecular simulations in structure-based drug design. Phys Chem Chem Phys (2014) 0.86
Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA capture. J Virol (2005) 0.86
HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action. Retrovirology (Auckl) (2008) 0.86
Binding modes of diketo-acid inhibitors of HIV-1 integrase: a comparative molecular dynamics simulation study. J Mol Graph Model (2011) 0.85
Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother (2008) 0.85
Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. PLoS One (2012) 0.84
Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. J Virol (2006) 0.84
Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. Antimicrob Agents Chemother (2008) 0.84
Biochemical and biophysical analyses of concerted (U5/U3) integration. Methods (2008) 0.83
Host Factors in Retroviral Integration and the Selection of Integration Target Sites. Microbiol Spectr (2014) 0.83
Direct detection of structurally resolved dynamics in a multiconformation receptor-ligand complex. J Am Chem Soc (2011) 0.83
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother (2016) 0.82
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors. J Virol (2014) 0.82
6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integrase. Bioorg Med Chem Lett (2011) 0.81
Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients. Clin Med Rev Ther (2011) 0.80
Virtual screening models for prediction of HIV-1 RT associated RNase H inhibition. PLoS One (2013) 0.80
HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex. J Mol Biol (2011) 0.80
Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects. Acta Naturae (2011) 0.78
Raltegravir in the management of HIV-infected patients. Drug Des Devel Ther (2009) 0.78
Computational methods in drug discovery. Beilstein J Org Chem (2016) 0.78
Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorg Med Chem (2011) 0.78
Role of raltegravir in the management of HIV-1 infection. HIV AIDS (Auckl) (2011) 0.77
Computer tools in the discovery of HIV-1 integrase inhibitors. Future Med Chem (2010) 0.77
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy. Infect Drug Resist (2010) 0.76
Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2013) 0.76
A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid. Biophys J (2007) 0.76
Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity. Iran J Pharm Res (2016) 0.75
Mechanistic and pharmacological analyses of HIV-1 integration. Methods (2009) 0.75
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
A quantitative assay for HIV DNA integration in vivo. Nat Med (2001) 8.67
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
HIV chemotherapy. Nature (2001) 3.63
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci U S A (2000) 3.26
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A (2000) 3.00
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med (1993) 2.98
Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A (1999) 2.69
Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol (1998) 2.49
Discovery of a novel binding trench in HIV integrase. J Med Chem (2004) 2.09
HIV integrase structure and function. Adv Virus Res (1999) 2.08
HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res (1999) 2.06
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem (2002) 1.80
Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J Med Chem (2003) 1.55
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Sampling and efficiency of metric matrix distance geometry: a novel partial metrization algorithm. J Biomol NMR (1992) 1.43
4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem (2000) 1.30
Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase. J Virol (1997) 1.17
Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J Med Chem (2004) 1.16
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob Agents Chemother (2002) 1.01
Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr Opin Drug Discov Devel (2001) 0.92
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe (2008) 6.24
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol (2005) 4.78
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell (2002) 4.37
Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog (2009) 4.24
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet (2009) 3.65
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett (2005) 3.50
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A (2002) 3.40
Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science (2006) 3.37
SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab (2008) 3.35
Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nat Cell Biol (2006) 3.14
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO J (2002) 3.11
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem (2008) 3.09
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem (2003) 2.82
Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature (2002) 2.78
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev (2012) 2.70
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
Complexin clamps asynchronous release by blocking a secondary Ca(2+) sensor via its accessory α helix. Neuron (2010) 2.52
Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron (2013) 2.51
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol (2006) 2.50
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol (2004) 2.47
Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem (2004) 2.46
Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol (2002) 2.44
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (2014) 2.27
NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2. Gut (2011) 2.26
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol (2011) 2.20
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res (2011) 2.15
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 2.12
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
The intra-S phase checkpoint targets Dna2 to prevent stalled replication forks from reversing. Cell (2012) 2.07
Association of high-risk human papillomavirus infection with oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol (2013) 2.07
Genetics of metabolic variations between Yersinia pestis biovars and the proposal of a new biovar, microtus. J Bacteriol (2004) 2.04
Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol (2003) 2.03
Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem (2012) 2.01
Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS (2010) 2.00
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A (2003) 1.99
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med (2003) 1.98
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther (2011) 1.92
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology (2010) 1.92
Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem (2003) 1.89
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
RIM proteins activate vesicle priming by reversing autoinhibitory homodimerization of Munc13. Neuron (2011) 1.89
Structure-based design of potent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem (2004) 1.87
Reverse and conventional chemical ecology approaches for the development of oviposition attractants for Culex mosquitoes. PLoS One (2008) 1.87
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother (2004) 1.86
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis (2012) 1.85
Intermittent hypoxia is associated with oxidative stress and spatial learning deficits in the rat. Am J Respir Crit Care Med (2003) 1.85
Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol (2011) 1.83
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (2002) 1.82
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother (2009) 1.80
TDRD3 is an effector molecule for arginine-methylated histone marks. Mol Cell (2010) 1.80
The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol (2003) 1.80
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem (2002) 1.80
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev (2012) 1.79
Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol (2004) 1.78